TRIP4

Across TCGA pan-cancer cohorts, TRIP4 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated TRIP4 data layer compared with 21 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher TRIP4 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated TRIP4 expression acts as an unfavorable survival marker, although some lineages such as UCEC and LSCC show a favorable association.

UCEC, PDAC, and LUAD are the cancer types where TRIP4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	0.962	0.850	.008	18	view →
PDAC	OS	Quartile	II,III,IV	0.360	0.650	.010	18	view →
LUAD	DFS	Median	II,III,IV	0.268	0.699	<.001	5	view →
GBM	OS	Quartile	All	0.771	0.899	.023	3	view →
LSCC	DFS	Quartile	All	1.000	0.519	.043	2	view →
CCRCC	DFS	Tertile	II,III,IV	0.784	0.260	.035	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

TRIP4–UCEC (DFS)

Open the UCEC breakdown →